Latest & greatest articles for measles

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on measles or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on measles and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for measles

61. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. (PubMed)

Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. To investigate the duration of the presence of maternal antibodies to measles in infants.Prospective study (May 2006 to November 2008).Five hospitals in the Province of Antwerp, Belgium.Of 221 pregnant women recruited, 207 healthy woman-infant pairs were included-divided into a vaccinated group (n=87) and naturally immune group (n=120), according to vaccination documents and history.Measles IgG (...) study describes a very early susceptibility to measles in infants of both vaccinated women and women with naturally acquired immunity. This finding is important in view of recent outbreaks and is an argument for timeliness of the first dose of a measles vaccine and vaccination of travelling or migrating children under the age of 1 year.

Full Text available with Trip Pro

2010 BMJ

62. Effectiveness of measles vaccination and vitamin A treatment

Effectiveness of measles vaccination and vitamin A treatment Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

63. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. (PubMed)

Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. To examine in a randomised trial whether a 25% difference in mortality exists between 4.5 months and 3 years of age for children given two standard doses of Edmonston-Zagreb measles vaccines at 4.5 and 9 months of age compared with those given one dose of measles vaccine at 9 months of age (current policy).Randomised controlled trial.The Bandim Health Project, Guinea (...) -Bissau, which maintains a health and demographic surveillance system in an urban area.6648 children aged 4.5 months of age who had received three doses of diphtheria-tetanus-pertussis vaccine at least four weeks before enrolment. A large proportion of the children (80%) had previously taken part in randomised trials of neonatal vitamin A supplementation.Children were randomised to receive Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age (group A), no vaccine at 4.5 months and Edmonston

Full Text available with Trip Pro

2010 BMJ Controlled trial quality: predicted high

64. Chinese medicinal herbs for measles. (PubMed)

Chinese medicinal herbs for measles. Measles is an infectious disease caused by the Morbilli virus. Chinese physicians believe that medicinal herbs are effective in alleviating symptoms and preventing complications. Chinese herbal medicines are dispensed according to the particular symptoms. This is an update of a Cochrane review first published in 2006.To assess the effectiveness and possible adverse effects of Chinese medicinal herbs in treating measles.We searched the Cochrane Central (...) ) in which patients with measles without complications were treated with Chinese medicinal herbs.Three review authors (YZ, RG, TW) independently assessed trial quality and extracted data. We telephone interviewed the study authors for missing information regarding participant allocation. Some trials allocated participants according to the sequence they were admitted to the trials, that is to say, by using a pseudo-random allocation method; none of the trials concealed the allocation or blinding method.We

2009 Cochrane

65. Measles in Europe: an epidemiological assessment. (PubMed)

Measles in Europe: an epidemiological assessment. Measles persists in Europe despite the incorporation of the measles vaccine into routine childhood vaccination programmes more than 20 years ago. Our aim was therefore to review the epidemiology of measles in relation to the goal of elimination by 2010.National surveillance institutions from 32 European countries submitted data for 2006-07. Data for age-group, diagnosis confirmation, vaccination, hospital treatment, the presence of acute (...) encephalitis as a complication of disease, and death were obtained. 30 countries also supplied data about importation of disease. Clinical, laboratory-confirmed, and epidemiologically linked cases that met the requirements for national surveillance were analysed. Cases were separated by age: younger than 1 year, 1-4 years, 5-9 years, 10-14 years, 15-19 years, and older than 20 years. Countries with indigenous measles incidence per 100 000 inhabitants per year of 0, less than 0.1, 0.1-1, and more than 1

2009 Lancet

66. Cost-effectiveness of supplementary immunization for measles in India

Cost-effectiveness of supplementary immunization for measles in India Cost-effectiveness of supplementary immunization for measles in India Cost-effectiveness of supplementary immunization for measles in India Dabral M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of a supplementary immunisation activity for measles compared with a standard single-dose vaccine programme for children in districts of India with low vaccination coverage. The author concluded that the supplementary immunisation activity was cost-effective in reducing mortality and morbidity from measles. The methods and reporting were mostly satisfactory, but the selection and details of the clinical and economic data sources

2009 NHS Economic Evaluation Database.

67. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age (PubMed)

Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age This study evaluated the safety, tolerability, and immunogenicity of live attenuated influenza vaccine administered concurrently with measles-mumps-rubella vaccine and varicella vaccine to healthy children 12 to 15 months of age.Children were assigned randomly to receive (1) measles-mumps-rubella vaccine, varicella (...) vaccine, and intranasal placebo on day 0, followed by 1 dose of live attenuated influenza vaccine on days 42 and 72; (2) measles-mumps-rubella, varicella, and live attenuated influenza vaccines on day 0, followed by a second dose of live attenuated influenza vaccine on day 42 and intranasally administered placebo on day 72; or (3) 1 dose of live attenuated influenza vaccine on days 0 and 42, followed by measles-mumps-rubella and varicella vaccines on day 72. Serum samples were collected before

2008 EvidenceUpdates Controlled trial quality: uncertain

68. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children (PubMed)

Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children The measles-mumps-rubella vaccine has been associated with immune thrombocytopenia purpura in 2 small studies.By using the Vaccine Safety Datalink, we identified measles-mumps-rubella-vaccinated children aged 1 to 18. A case of immune thrombocytopenia purpura was defined as a patient with a platelet count of < or = 50,000/microL with clinical bleeding and normal red and white blood cell indices (...) . The immune thrombocytopenia purpura incidence rates during exposed (42 days after vaccination) and unexposed time periods were determined. A retrospective cohort of vaccinated children was used to determine incident rate ratios for children aged 1 to 18 years, 12 to 23 months, and 12 to 15 months.A total of 1,036,689 children received 1,107,814 measles-mumps-rubella vaccinations; there were 259 confirmed patients with immune thrombocytopenia purpura. Because only 5 exposed cases occurred after age 2

2008 EvidenceUpdates

69. Factors associated with uptake of measles, mumps, and rubella vaccine (MMR) and use of single antigen vaccines in a contemporary UK cohort: prospective cohort study. (PubMed)

Factors associated with uptake of measles, mumps, and rubella vaccine (MMR) and use of single antigen vaccines in a contemporary UK cohort: prospective cohort study. To estimate uptake of the combined measles, mumps, and rubella vaccine (MMR) and single antigen vaccines and explore factors associated with uptake and reasons for not using MMR.Nationally representative cohort study.Children born in the UK, 2000-2.14,578 children for whom data on immunisation were available.Immunisation status

Full Text available with Trip Pro

2008 BMJ

70. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs

Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs Danerseau AM, Robinson JL CRD summary The authors concluded that available (...) published data on the efficacy and safety of live viral vaccines was insufficient to derive evidence-based guidelines for use of such vaccines in transplant recipients on immunosuppression. The reliability of the authors’ conclusion is unclear given multiple flaws in the review methods and small number of low quality studies reviewed. Authors' objectives To assess the efficacy and safety of live viral vaccines for measles, mumps, rubella and varicella (chicken pox) in post-transplant patients receiving

2008 DARE.

71. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. (PubMed)

Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. To examine the protective efficacy of measles vaccination in infants in a low income country before 9 months of age.Randomised clinical trial.1333 infants aged 4.5 months: 441 in treatment group and 892 in control group.Urban area in Guinea-Bissau.Measles vaccination using standard titre Edmonston-Zagreb vaccine at 4.5 months of age.Vaccine efficacy (...) against measles infection, admission to hospital for measles, and measles mortality before standard vaccination at 9 months of age.28% of the children tested at 4.5 months of age had protective levels of maternal antibodies against measles at enrolment. After early vaccination against measles 92% had measles antibodies at 9 months of age. A measles outbreak offered a unique situation for testing the efficacy of early measles vaccination. During the outbreak, 96 children developed measles; 19

Full Text available with Trip Pro

2008 BMJ Controlled trial quality: uncertain

72. WITHDRAWN: Antibiotics for preventing pneumonia in children with measles. (PubMed)

WITHDRAWN: Antibiotics for preventing pneumonia in children with measles. Measles causes more than a million deaths a year, of which most are children under five years of age who die from pneumonia.The objective of this review was to assess the effects of antibiotics given to children with measles on reducing pneumonia or mortality, and to assess whether antibiotics should be given to all children with measles in communities with a high fatality rate.We searched MEDLINE (1966 - 1999), EMBASE (...) with measles. Available evidence suggests that antibiotics should be given only if a child has clinical signs of pneumonia or other evidence of sepsis.

2007 Cochrane

73. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. (PubMed)

Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. In 2002, the UN General Assembly Special Session on Children adopted a goal to reduce deaths owing to measles by half by the end of 2005, compared with 1999 estimates. We describe efforts and progress made towards this goal.We assessed trends in immunisation against measles on the basis of national implementation of the WHO/UNICEF comprehensive strategy for measles mortality reduction (...) , and the provision of a second opportunity for measles immunisation. We used a natural history model to evaluate trends in mortality due to measles.Between 1999 and 2005, according to our model mortality owing to measles was reduced by 60%, from an estimated 873,000 deaths (uncertainty bounds 634,000-1,140,000) in 1999 to 345,000 deaths (247,000-458,000) in 2005. The largest percentage reduction in estimated measles mortality during this period was in the western Pacific region (81%), followed by Africa (75

2007 Lancet

74. Susceptibility to measles, mumps, and rubella in newly arrived adult immigrants and refugees. (PubMed)

Susceptibility to measles, mumps, and rubella in newly arrived adult immigrants and refugees. Despite effective vaccination programs for measles, mumps, and rubella in the United States and Canada, outbreaks continue to occur in susceptible subgroups, such as foreign-born persons.To determine the susceptibility of newly arrived immigrants and refugees to measles, mumps, and rubella.Seroprevalence study.Two hospitals and three community clinics in Montreal, Quebec, Canada.1480 adult immigrants (...) and refugees who were recruited from October 2002 to December 2004.Sociodemographic and clinical data and serology for measles, mumps, and rubella.Thirty-six percent (range, 22% to 54%) of the study population was nonimmune to at least 1 of the 3 diseases. This proportion varied by age, sex, and region of origin. In multivariate analysis and after adjustment for region of origin, age, and socioeconomic factors, immigrant women had higher odds (odds ratio, 2.1) of being immune to measles (95% CI, 1.2 to 3.8

2007 Annals of Internal Medicine

75. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. (PubMed)

Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. Measles was declared eliminated from the United States in 2000 but remains endemic worldwide. In 2005, a 17-year-old unvaccinated girl who was incubating measles returned from Romania, creating the largest documented outbreak of measles in the United States since 1996.We conducted a case-series investigation, molecular typing of viral isolates, surveys of rates of vaccination coverage (...) , interviews regarding attitudes toward vaccination, and cost surveys.Approximately 500 persons attended a gathering with the index patient one day after her return home. Approximately 50 lacked evidence of measles immunity, of whom 16 (32 percent) acquired measles at the gathering. During the six weeks after the gathering, a total of 34 cases of measles were confirmed. Of the patients with confirmed measles, 94 percent were unvaccinated, 88 percent were less than 20 years of age, and 9 percent were

2006 NEJM

76. Chinese medicinal herbs for measles. (PubMed)

Chinese medicinal herbs for measles. Measles is an infectious disease caused by Morbillivirus. Chinese physicians believe that medicinal herbs are effective in alleviating symptoms and preventing complications. Chinese herbal medicines are dispensed according to the particular symptoms.To assess the effectiveness and possible adverse events of Chinese medicinal herbs in treating measles.We searched the Cochrane Central Register of Controlled Clinical Trials (CENTRAL) (The Cochrane Library Issue (...) 4, 2005); MEDLINE (1966 to June 2005); EMBASE (1980 to June 2005); the Chinese Biomedical Database (1976 to June 2005); VIP Information (1989 to June 2005); China National Knowledge Infrastructure (CNKI) (1994 to June 2005); and the metaRegister of Controlled Trials was searched for ongoing trials.Randomised controlled trials (RCTs) in which patients with measles without complications were treated with Chinese medicinal herbs were included.The primary outcome measure was death from any cause

2006 Cochrane

77. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?

Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective? Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective? Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective? Celikbas A, Ergonul O, Aksaray S, Tuygun N, Esener H, Tanir G, Eren S, Baykam N, Guvener E (...) , Dokuzoguz B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study investigated the use of a programme for screening health care workers for their immunity to measles, rubella, mumps and varicella (MMRV), with those with no immunity

2006 NHS Economic Evaluation Database.

78. Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau. (PubMed)

Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau. To investigate whether prophylactic antibiotics can prevent complications of measles.Community based, randomised, double blind, placebo controlled trial.Bandim Health Project study area in Bissau, Guinea-Bissau, west Africa.84 patients with measles during a measles epidemic in Bissau in 1998 (fewer than originally planned owing (...) to interruption by war).Sulfamethoxazole-trimethoprim (co-trimoxazole) or placebo for seven days.Pneumonia and admission to hospital. Also weight change during the first month of infection, diarrhoea, severe fever, oral thrush, stomatitis, conjunctivitis, and otitis media.The median age of the patients with measles was 5.4 (range 0.49-24.8) years. One of 46 participants who received co-trimoxazole developed pneumonia, in contrast to six of 38 participants who received placebo (odds ratio 0.08 (95% confidence

Full Text available with Trip Pro

2006 BMJ Controlled trial quality: predicted high

79. Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism

Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism Article

Full Text available with Trip Pro

2005 Evidence-Based Nursing

80. Measles, mumps, and rubella vaccine was not associated with autism in children

Measles, mumps, and rubella vaccine was not associated with autism in children Measles, mumps, and rubella vaccine was not associated with autism in children | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Measles, mumps, and rubella vaccine was not associated with autism in children Article Text Causation Measles, mumps, and rubella vaccine was not associated with autism in children Free Stephanie Wright , CFNP, CPNP, PhD Statistics from

Full Text available with Trip Pro

2004 Evidence-Based Nursing